Douglas Laird

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

Lijun Zhou, Mingli Sun, Xian Zhang et al. · Oncogene · 2015 · 393 citations

Medicine, Oncology, Pharmacology +12

The Antiangiogenic Agents SU5416 and SU6668 Increase the Antitumor Effects of Fractionated Irradiation

Shoucheng Ning, Douglas Laird, Julie M. Cherrington et al. · Radiation Research · 2002 · 124 citations

Medicine, Oncology, Radiation Oncology +17

A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors

Kyriakos P. Papadopoulos, B. Markman, Josep Tabernero et al. · Journal of Clinical Oncology · 2008 · 27 citations

Medicine, Oncology, Pharmacology +16

Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors

Joerg Bussenius, Neel K. Anand, Charles M. Blazey et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 24 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors

Lee S. Rosen, Peter S. Galatin, J. M. Fehling et al. · Journal of Clinical Oncology · 2008 · 17 citations

Medicine, Oncology, Pharmacology +14